Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for a new weekly transdermal patch formulation (once-weekly administration formulation) of Eisai's Alzheimer’s treatment, Aricept for review.
Subscribe to our email newsletter
Aricept transdermal patch NDA, if approved, is expected to be marketed by Eisai Inc, Easai’s US subsidiary, where it will co-promote the patch in collaboration with Pfizer.
Easai said that the new Aricept transdermal patch is developed by Teikoku Pharma USA, under an agreement signed between Eisai and its parent company Teikoku Seiyaku in 2009.
Aricept transdermal patch was developed to provide a potential new treatment option to Alzheimer’s disease patients who have trouble swallowing.